Double-blind placebo-controlled trial of intranasal IgE pentapeptide.

Abstract

The safety and efficacy of intranasal HEPP (IgE pentapeptide) was evaluated in 30 patients with IgE-mediated allergic rhinitis. Statistically and clinically significant differences were observed in the degree of clinical improvement between HEPP and placebo groups. IgE pentapeptide 0.5% intranasal solution appears to be safe and effective in the treatment of allergic rhinitis.

• Authors: B M Prenner
• Journal: Annals of allergy (Ann Allergy) Vol. 58 Issue 5 Pg. 332-5 (May 1987) ISSN: 0003-4738 [Print] United States
• PMID: 3578925 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Peptide Fragments
• Placebos
• Immunoglobulin E
• pentigide

Topics

• Administration, Intranasal
• Adolescent
• Adult
• Child
• Double-Blind Method
• Female
• Humans
• Immunoglobulin E (administration & dosage)
• Male
• Middle Aged
• Peptide Fragments (administration & dosage)
• Placebos